Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

Investors have largely abandoned much of the healthcare space in favor of tech. But as tech falters, some strategists see the underrated sector as being the perfect tech hedge.

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

While many report positive results after taking the medication, experts warn significant weight loss can negatively impact ...

We recently published a list of 12 Best FMCG Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Mondelez International, Inc.

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks ...

A study finds GLP-1 weight-loss drugs may pose vision risks, revealing an unexpected medical irony. A paradoxical insight: ...

Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.

Although reports of vision problems with weight loss drugs are still rare, researchers say there is cause for concern because of how widespread the medications are becoming. A 2024 study found that 12 ...